273 related articles for article (PubMed ID: 17509162)
21. Ixabepilone: a new microtubule-targeting agent for breast cancer.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
[TBL] [Abstract][Full Text] [Related]
22. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
Andreopoulou E; Muggia F
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
[TBL] [Abstract][Full Text] [Related]
24. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
Goodin S
Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860
[TBL] [Abstract][Full Text] [Related]
25. Discovery and development of the epothilones : a novel class of antineoplastic drugs.
Reichenbach H; Höfle G
Drugs R D; 2008; 9(1):1-10. PubMed ID: 18095749
[TBL] [Abstract][Full Text] [Related]
26. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
27. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
28. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues.
Fornier MN
Clin Breast Cancer; 2007 Oct; 7(10):757-63. PubMed ID: 18021476
[TBL] [Abstract][Full Text] [Related]
29. Novel cytotoxic agents: epothilones.
Goodin S
Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
[TBL] [Abstract][Full Text] [Related]
30. Epothilones as Natural Compounds for Novel Anticancer Drugs Development.
Villegas C; González-Chavarría I; Burgos V; Iturra-Beiza H; Ulrich H; Paz C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047035
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
[TBL] [Abstract][Full Text] [Related]
32. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
Pivot X; Villanueva C; Chaigneau L; Nguyen T; Demarchi M; Maurina T; Stein U; Borg C
Expert Opin Investig Drugs; 2008 Apr; 17(4):593-9. PubMed ID: 18363523
[TBL] [Abstract][Full Text] [Related]
33. Current perspectives of epothilones in breast cancer.
Cardoso F; de Azambuja E; Lago LD
Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
[TBL] [Abstract][Full Text] [Related]
34. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
Pabla N; Sparreboom A
Clin Cancer Res; 2015 Mar; 21(6):1237-9. PubMed ID: 25770292
[TBL] [Abstract][Full Text] [Related]
35. The epothilones: translating from the laboratory to the clinic.
Lee JJ; Swain SM
Clin Cancer Res; 2008 Mar; 14(6):1618-24. PubMed ID: 18347162
[TBL] [Abstract][Full Text] [Related]
36. Ixabepilone for the treatment of taxane-refractory breast cancer.
Moulder SL
Future Oncol; 2008 Jun; 4(3):333-40. PubMed ID: 18518758
[TBL] [Abstract][Full Text] [Related]
37. Advances in breast cancer treatment: the emerging role of ixabepilone.
Frye DK
Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882
[TBL] [Abstract][Full Text] [Related]
38. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
Altmann KH; Memmert K
Prog Drug Res; 2008; 66():273, 275-334. PubMed ID: 18416309
[TBL] [Abstract][Full Text] [Related]
39. Epothilones in the treatment of ovarian cancer.
Diaz-Padilla I; Oza AM
Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies.
Gupta D; Mani S
Expert Opin Drug Saf; 2009 Jan; 8(1):81-8. PubMed ID: 19236220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
